Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 87 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement

Kalra Sanjay, Aamir A H, Raza Abbas, Das A K, Azad Khan A K, Shrestha Dina, Qureshi Md Faisal, Md Fariduddin, Pathan Md Faruque, Jawad Fatema, Bhattarai Jyoti, Tandon Nikhil, Somasundaram Noel, Katulanda Prasad, Sahay Rakesh, Dhungel Sanjib, Bajaj Sarita, Chowdhury Subhankar, Ghosh Sujoy, Madhu S V, Ahmed Tofail, Bulughapitiya Uditha

Year : 2015| Volume: 19| Issue : 5 | Page no: 577-596

   This article has been cited by
1 Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
Lawrence A. Leiter,Marina V. Shestakova,Ilhan Satman
Diabetology & Metabolic Syndrome. 2018; 10(1)
[Pubmed]  [Google Scholar] [DOI]
2 Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association
Annabelle Santos Volgman,Latha S. Palaniappan,Neelum T. Aggarwal,Milan Gupta,Abha Khandelwal,Aruna V. Krishnan,Judith H. Lichtman,Laxmi S. Mehta,Hena N. Patel,Kevin S. Shah,Svati H. Shah,Karol E. Watson
Circulation. 2018; 138(1)
[Pubmed]  [Google Scholar] [DOI]
3 Bonus Effects of Antidiabetic Drugs: Possible Beneficial Effects on Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis
Camila A. Pereira,Fernando S. Carneiro,Takayuki Matsumoto,Rita C. Tostes
Basic & Clinical Pharmacology & Toxicology. 2018;
[Pubmed]  [Google Scholar] [DOI]
4 The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
Stephen Colagiuri,David Matthews,Lawrence A. Leiter,Siew Pheng Chan,Giorgio Sesti,Michel Marre
Diabetes Research and Clinical Practice. 2018; 143: 1
[Pubmed]  [Google Scholar] [DOI]
5 New Medications for the Treatment of Diabetes
Satish K. Garg,Dominique Giordano,Tyler Gallo,Viral N. Shah
Diabetes Technology & Therapeutics. 2017; 19(S1): S-128
[Pubmed]  [Google Scholar] [DOI]
6 Clinical practice points for diabetes management during RAMADAN fast
Shaukat Sadikot,K. Jothydev,A.H. Zargar,Jamal Ahmad,S.R. Arvind,Banshi Saboo
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;
[Pubmed]  [Google Scholar] [DOI]
7 Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial
S. T. Azar,A. Echtay,W. M. Wan Bebakar,S. Al Araj,A. Berrah,M. Omar,A. Mutha,K. Tornøe,M. S. Kaltoft,N. Shehadeh
Diabetes, Obesity and Metabolism. 2016;
[Pubmed]  [Google Scholar] [DOI]
8 Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics
Dipali Dhawan,Harish Padh
Diabetes Research and Clinical Practice. 2016; 121: 35
[Pubmed]  [Google Scholar] [DOI]
9 Mortality and Cardiovascular Risk of Sulfonylureas in South Asian, Chinese and Other Canadians with Diabetes
Calvin Ke,Steve Morgan,Kate Smolina,Danijela Gasevic,Hong Qian,Nadia Khan
Canadian Journal of Diabetes. 2016;
[Pubmed]  [Google Scholar] [DOI]


Read this article